SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...

Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...

Clearmind Issues Shareholder Letter Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...